Abstract

 CADTH recommends that Jakavi be reimbursed by public drug plans for the treatment of steroid-refractory or steroid-dependent acute graft-versus-host disease (aGvHD) if certain conditions are met.
 Jakavi should only be covered to treat adults and pediatric patients aged 12 years and older who have steroid-refractory or steroid-dependent aGvHD.
 Jakavi should only be reimbursed if prescribed by a specialist who has experience in the diagnosis and management of patients with aGvHD, and the cost of Jakavi is reduced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
